Phosphoproteomic biomarkers predicting histologic nonalcoholic steatohepatitis and fibrosis

Journal of Proteome Research

Volumn 9, Issue 6, 2010, Pages 3218-3224

  Younossi, Zobair M ^a,c   Baranova, Ancha ^a,b,c   Stepanova, Maria ^a,c   Page, Sandra ^b   Calvert, Valerie S ^a,b   Afendy, Arian ^c   Goodman, Zachary ^a,c   Chandhoke, Vikas ^b,c   Liotta, Lance ^b,c,d   Petricoin, Emanuel ^c,d  

^a INOVA FAIRFAX HOSPITAL   (United States)

^b GEORGE MASON UNIVERSITY   (United States)

^c BETTY AND GUY BEATTY CENTER FOR INTEGRATED RESEARCH   (United States)

^d GEORGE MASON UNIVERSITY   (United States)

Author keywords

biomarker; fibrosis; Nonalcoholic fatty liver disease (NAFLD); nonalcoholic steatohepatitis (NASH); reverse phase protein microarrays (RPMA)

Indexed keywords

CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; INSULIN RECEPTOR SUBSTRATE 1; PROTEIN KINASE B;

ADULT; ARTICLE; CLINICAL MODEL; COHORT ANALYSIS; COMBINATION MODEL; DISEASE COURSE; DISEASE MARKER; FEMALE; HUMAN; HUMAN TISSUE; INTRAABDOMINAL FAT; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; PROCESS MODEL; PROTEIN MICROARRAY; PROTEIN PHOSPHORYLATION; PROTEOMICS; RELIABILITY; REVERSE PHASE PROTEIN MICROARRAY;

ADIPOSE TISSUE; ADULT; AREA UNDER CURVE; BIOLOGICAL MARKERS; COHORT STUDIES; FATTY LIVER; FEMALE; HISTOCYTOCHEMISTRY; HUMANS; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PHOSPHOPROTEINS; PREDICTIVE VALUE OF TESTS; REGRESSION ANALYSIS; REPRODUCIBILITY OF RESULTS; SIGNAL TRANSDUCTION;

EID: 77954578369     PISSN: 15353893     EISSN: 15353907     Source Type: Journal    
DOI: 10.1021/pr100069e     Document Type: Article

References (30)

1. Marchesini, G.; Brizi, M.; Bianchi, G.; Tomassetti, S.; Bugianesi, E.; Lenzi, M.; et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001, 50, 1844-1850.
2. Sanyal, A. J.; Campbell-Sargent, C.; Mirshahi, F.; Rizzo, W. B.; Contos, M. J.; Sterling, R. K.; et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001, 120, 1183-1192.
3. Choudhury, J.; Sanyal, A. J. Insulin resistance in NASH. Front. Biosci. 2005, 10, 1520-1533.
4. Li, Z.; Clark, J.; Diehl, A. M. The liver in obesity and type 2 diabetes mellitus. Clin. Liver Dis. 2002, 6, 867-877.
5. Chitturi, S.; Abeygunasekera, S.; Farrell, G. C.; Holmes-Walker, J.; Hui, J. M.; et al. NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002, 35, 373-379.
6. Browning, J. D.; Szczepaniak, L. S.; Dobbins, R; Nuremberg, P; Horton, J. D.; Cohen, J. C.; Grundy, S. M.; Hobbs, H. H. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004, 40, 1387-1395.
7. Lavine, J. E.; Schwimmer, J. B. Nonalcoholic fatty liver disease in the pediatric population. Clin. Liver Dis. 2004, 8, 549-558.
8. Neuschwander-Tetri, B. A. Nonalcoholic steatohepatitis and the metabolic syndrome. Am. J. Med. Sci. 2005, 330, 326-335.
9. Younossi, Z. M.; Diehl, A. M.; Ong, J. P. Nonalcoholic fatty liver disease: an agenda for clinical research. Hepatology 2002, 35, 746-752.
10. Baranova, A.; Younossi, Z. M. Adipokines in nonalcoholic fatty liver disease. In Nutrition and Health: Adipose Tissue and Adipokines in Health and Disease; Fantuzzi, G., Mazzone, T., Eds.; Humana Press Inc.: Totowa, NJ, 2006.
11. Matteoni, C. A.; Younossi, Z. M.; Gramlich, T.; Boparai, N.; Liu, Y. C.; McCullough, A. J. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999, 116, 1413-1419.
12. Duvnjak, M.; Lerotić, I.; Bars?́, N.; Tomasić, V.; Virović Jukić, L.; Velagić, V. Pathogenesis and management issues for non-alcoholic fatty liver disease. World J. Gastroenterol. 2007, 13, 4539-4550.
13. Ratziu, V.; Charlotte, F.; Heurtier, A.; Gombert, S.; Giral, P.; Bruckert, E.; et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005, 128, 1898-1906.
14. Collantes, R.; Ong, J. P.; Younossi, Z. M. Nonalcoholic fatty liver disease and the epidemic of obesity. Clev. Clin. J. Med. 2004, 71, 657-664.
15. Tobari, M.; Hashimoto, E.; Yatsuji, S.; Torii, N.; Shiratori, K. Imaging of nonalcoholic steatohepatitis: advantages and pitfalls of ultrasonography and computed tomography. Intern. Med. 2009, 48, 739-746.
16. Delgado, J. S. Evolving trends in nonalcoholic fatty liver disease. Eur. J. Intern. Med. 2008, 19, 75-82.
17. Espina, V.; Geho, D.; Mehta, A. I.; Petricoin, E. F., III; Liotta, L. A.; Rosenblatt, K. P. Pathology of the future: molecular profiling for targeted therapy. Cancer Invest. 2005, 23, 36-46.
18. Calvert, V. S.; Collantes, R.; Elariny, H.; Afendy, A.; Baranova, A.; Mendoza, M.; et al. A systems biology approach to the pathogenesis of obesity-related nonalcoholic fatty liver disease using reverse phase protein microarrays for multiplexed cell signaling analysis. Hepatology 2007, 46, 166-172.
19. Bondini, S.; Kleiner, D. E.; Goodman, Z. D.; Gramlich, T.; Younossi, Z. M. Pathologic assessment of non-alcoholic fatty liver disease. Clin. Liver Dis. 2007, 11, 17-23.
20. Rayasam, G. V.; Tulasi, V. K.; Sodhi, R.; Davis, J. A.; Ray, A. Glycogen synthase kinase 3: more than a namesake. Br. J. Pharmacol. 2009, 156, 885-898.
21. Wagman, A. S.; Johnson, K. W.; Bussiere, D. E. Discovery and development of GSK3 inhibitors for the treatment of type 2 diabetes. Curr. Pharm. Des. 2004, 10, 1105-1137.
22. Rafiq, N.; Bai, C.; Fang, Y.; Srishord, M.; McCullough, A.; Gramlich, T.; Younossi, Z. M. Long-term follow-up of patients with nonalcoholic fatty liver. Clin. Gastroenterol. Hepatol. 2009, 7, 234-238.
23. Che, J.; Chan, E. S.; Cronstein, B. N. Adenosine A2A receptor occupancy stimulates collagen expression by hepatic stellate cells via pathways involving protein kinase A, Src, and extracellular signal-regulated kinases 1/2 signaling cascade or p38 mitogenactivated protein kinase signaling pathway. Mol. Pharmacol. 2007, 72, 1626-1636.
24. McKnight, G. S.; Cummings, D. E.; Amieux, P. S.; Sikorski, M. A.; Brandon, E. P.; Planas, J. V.; Motamed, K; Idzerda, R. L. Cyclic AMP, PKA, and the physiological regulation of adiposity. Recent Prog. Horm. Res. 1998, 53, 139-159.
25. Antunes, T. T.; Gagnon, A.; Bell, A.; Sorisky, A. Thyroid-stimulating hormone stimulates interleukin-6 release from 3T3-L1 adipocytes through a cAMP-protein kinase A pathway. Obes. Res. 2005, 13, 2066-7201.
26. Wieckowska, A.; Papouchado, B. G.; Li, Z.; Lopez, R.; Zein, N. N.; Feldstein, A. E. Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. Am. J. Gastroenterol. 2008, 103, 1372-1379.
27. Baranova, A.; Younossi, Z. M. The future is around the corner: Noninvasive diagnosis of progressive nonalcoholic steatohepatitis. Hepatology 2008, 47, 373-375.
28. Guha, I. N.; Parkes, J.; Roderick, P.; Chattopadhyay, D.; Cross, R.; Harris, S.; et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology 2008, 47, 455-460.
29. Younossi, Z. M.; Jarrar, M.; Nugent, C.; Randhawa, M.; Afendy, M.; Stepanova, M.; et al. A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH). Obes. Surg. 2008, 18, 1430-1437.
30. Cohen, P. Protein kinases-the major drug targets of the twenty-first century? Nat. Rev. Drug Discovery 2002, 1, 309-315.